Clinical Trial Update: Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing two doses of post-transplant cyclophosphamide (PT-Cy) for graft-versus-host disease prophylaxis; status not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematologic Malignancy

Drugs mentioned

• PT-CY (post-transplant cyclophosphamide)

Snippet

Sponsor: National Research Center for Hematology, Russia | Conditions: Graft Versus Host Disease, Hematologic Malignancy | Phase 3 | Status: UNKNOWN